Related Experiment Video
Updated: Apr 19, 2026
10:47
Immuno-fluorescence Assay of Leptospiral Surface-exposed Proteins
Published on: July 1, 2011
16.3K
Cross-protection between experimental anti-leptospirosis bacterins
Cristina Corsi Dib1, Amane Paldês Gonçales2, Zenaide Maria de Morais2
1Laboratório de Tuberculose Centro de Pesquisa e Desenvolvimento de Sanidade Animal Instituto Biológico São PauloSP Brazil Laboratório de Tuberculose, Centro de Pesquisa e Desenvolvimento de Sanidade Animal, Instituto Biológico, São Paulo, SP, Brazil.
Summary
Experimental bacterins against leptospirosis demonstrated cross-protection in hamsters, effectively safeguarding against both homologous and heterologous strains. This indicates broader efficacy for anti-leptospirosis vaccines.
Area of Science:
- Veterinary Immunology
- Bacteriology
- Vaccinology
Background:
- Leptospirosis is a significant zoonotic disease caused by Leptospira bacteria.
- Monovalent bacterins are developed to target specific Leptospira serovars.
- Cross-protection between different Leptospira serovars is crucial for effective vaccination strategies.
Purpose of the Study:
- To investigate cross-protection between two experimental monovalent anti-leptospirosis bacterins.
- To evaluate the efficacy of these bacterins against homologous and heterologous Leptospira strains.
- To compare experimental bacterins with a commercial polyvalent vaccine.
Main Methods:
- Production of two monovalent experimental bacterins using Leptospira serogroup Pomona strains (Fromm and GR6) with aluminum hydroxide adjuvant.
- Assessment of protection using the hamster potency test, evaluating disease prevention and kidney infection.
- Challenge with homologous and heterologous Leptospira strains according to international standards; evaluation of renal carriers post-challenge.
Main Results:
- Experimental bacterins conferred protection against both homologous and heterologous strains, confirming cross-protection.
- The commercial vaccine provided protection against disease but showed a high rate of renal carriers with the GR6 strain.
- Strain GR6 was isolated from pigs in Brazil, suggesting regional strain-specific challenges.
Conclusions:
- Experimental monovalent bacterins against Leptospira serogroup Pomona exhibit significant cross-protective capabilities.
- These findings support the potential for broader efficacy of bacterins targeting specific Leptospira serovars.
- Further research into regional Leptospira strain variations is warranted for vaccine development.
